Abstract:Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a poor but heterogeneous prognosis. Although the ALS Functional Rating Scale (ALSFRS) has been most commonly used, the decreases in ALSFRS do not follow a unitary linear trend and may be affected by factors other than disease condition. Group-based trajectory modeling (GBTM) is a method that can take the heterogeneity of declines in ALSFRS into consideration. We analyzed the 16-year trajectory of ALSFRS of patients in China using the GBTM method, and explored possible reasons for differences in the trajectories.Methods: 3,257 patients with sporadic ALS from January 2005 to May 2021 were recruited. ALSFRS scores were the dependent variable in the GBTM. To evaluate whether our results were transferable to other populations, Answer ALS and Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) were used as validation datasets. The baseline characteristics and laboratory indicators in different trajectory groups were compared. A Cox proportional hazards model was used to examine the association between primary outcomes and trajectory groups.Results: A model with four groups (rapid, moderate, slow, and very slow progression) was adopted. The four groups differed in sex (P=0.002), age at onset (P<0.001), diagnostic delay (P<0.001), phenotype (P<0.001), riluzole use (P=0.001), onset site (P<0.001), cerebrospinal fluid (CSF) protein levels (P=0.044), and neutrophil-to-lymphocyte ratio (NLR; P=0.011). Compared with the moderate progression group, the rapid progression group displayed an increased risk of progression to respiratory insufficiency or death (hazard ratio [HR]: 1.66, 95% confidence interval [CI]: 1.41 to 1.97), but the very slow progression group (HR: 0.06, 95% CI: 0.02 to 0.26) had a decreased risk. The trajectory groups with faster progression had a higher NLR and higher total protein in the CSF.Interpretation: This study provides a novel prognosis prediction method using the ALSFRS score trajectory. Notably, the higher NLR and higher total protein in the CSF of the trajectory groups with faster progression suggested that neuroinflammation may play a crucial role in ALS progression.Funding Information: Lu Chen has received the funding from the Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2022PY001]. Shengfeng Wang has received the funding from the Peking University Medicine Fund for World’s Leading Discipline or Discipline Cluster Development supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2021YJ035]. Siyan Zhan has received the funding from the Special Project for Director, China Center for Evidence Based Traditional Chinese Medicine [Grant number 2020YJSZX-2]. Dongsheng Fan has received the fundings from the National Natural Science Foundation of China (NSFC) under Grant [Number 81873784; 82071426].Declaration of Interests: None.Ethics Approval Statement: The protocol was approved by the institutional ethics committee of PUTH (IRB. No 00006761), and written informed consent was obtained from each patient.

Assessing disease progression in ALS: prognostic subgroups and outliers

Profiles of disease progression and predictors of mortality in Colombian patients with amyotrophic lateral sclerosis: a comprehensive longitudinal study

Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post‐onset ΔFS for study design and medical practice

ANALYSIS OF SURVIVAL TIME AND FUNCTIONAL PROGRESSION IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: A LONGITUDINAL STUDY

Clinical Determinants of Disease Progression in Amyotrophic Lateral Sclerosis—A Retrospective Cohort Study

Prognostic factors in ALS: A critical review

A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials

[Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].

Quantifying disease progression in amyotrophic lateral sclerosis

Prognostic Factors and Epidemiology of Amyotrophic Lateral Sclerosis in Southeastern United States

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model

Long-Term Longitudinal Progression Pattern of Amyotrophic Lateral Sclerosis: A Trajectory Analysis of a 16-Year Cohort in China

Analysis of survival in 106 patients with amyotrophic lateral sclerosis

Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm

Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up

A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Stratifying Disease Stages with Different Progression Rates Determined by Electrophysiological Tests in Patients with Amyotrophic Lateral Sclerosis.

Predictors of survival in frontotemporal lobar degeneration syndromes

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis

Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis